Anti-angiogenic treatment promotes triple-negative breast cancer invasion via vasculogenic mimicry

Cancer Biology and Therapy

Volumn 18, Issue 4, 2017, Pages 205-213

  Sun, Huizhi ^a   Zhang, Danfang ^a   Yao, Zhi ^a   Lin, Xian ^a   Liu, Jiameng ^a   Gu, Qiang ^a   Dong, Xueyi ^a   Liu, Fang ^a   Wang, Yi ^a   Yao, Nan ^a   Cheng, Siqi ^a   Li, Linqi ^a   Sun, Shuya ^a  

^a TIANJIN MEDICAL UNIVERSITY   (China)

Author keywords

Sunitinib; triple negative breast cancer; Twist1; vasculogenic mimicry

Indexed keywords

CD31 ANTIGEN; ENDOMUCIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; GELATINASE A; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MUCIN; PROGESTERONE RECEPTOR; SUNITINIB; TRANSCRIPTION FACTOR SLUG; TRANSCRIPTION FACTOR SNAIL; TWIST RELATED PROTEIN 1; UNCLASSIFIED DRUG; VASCULAR ENDOTHELIAL CADHERIN; VIMENTIN; ANGIOGENESIS INHIBITOR; CADHERIN; HIF1A PROTEIN, HUMAN; INDOLE DERIVATIVE; LEUKOCYTE ANTIGEN; MMP2 PROTEIN, HUMAN; NUCLEAR PROTEIN; PYRROLE DERIVATIVE; TWIST1 PROTEIN, HUMAN;

ADULT; AGED; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC THERAPY; ARTICLE; BREAST CANCER CELL LINE; BT474 CELL LINE; CANCER GROWTH; CANCER PATIENT; COMPARATIVE STUDY; CONTROLLED STUDY; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; FOLLOW UP; HS578T CELL LINE; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MCF-7 CELL LINE; MDA-MB-231 CELL LINE; MOUSE; NONHUMAN; PROTEIN EXPRESSION; TRIPLE NEGATIVE BREAST CANCER; TUMOR INVASION; TUMOR VASCULARIZATION; UPREGULATION; VASCULOGENIC MIMICRY; ANIMAL; BAGG ALBINO MOUSE; BREAST; DRUG EFFECTS; DRUG SCREENING; FLUORESCENT ANTIBODY TECHNIQUE; METABOLISM; MICROCIRCULATION; MIDDLE AGED; NEOVASCULARIZATION (PATHOLOGY); NUDE MOUSE; PATHOLOGY; TISSUE MICROARRAY; TREATMENT OUTCOME; TUMOR CELL LINE; VASCULARIZATION;

ADULT; AGED; ANGIOGENESIS INHIBITORS; ANIMALS; ANTIGENS, CD; BREAST; CADHERINS; CELL LINE, TUMOR; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; INDOLES; MATRIX METALLOPROTEINASE 2; MICE; MICE, INBRED BALB C; MICE, NUDE; MICROCIRCULATION; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOVASCULARIZATION, PATHOLOGIC; NUCLEAR PROTEINS; PYRROLES; TISSUE ARRAY ANALYSIS; TREATMENT OUTCOME; TRIPLE NEGATIVE BREAST NEOPLASMS; TWIST-RELATED PROTEIN 1; UP-REGULATION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 85015220474     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.1080/15384047.2017.1294288     Document Type: Article

References (43)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin 2009; 59:225-49; PMID:19474385; http://dx.doi.org/10.3322/caac.20006
2. Kalimutho M, Parsons K, Mittal D, Lopez JA, Srihari S, Khanna KK. Targeted therapies for triple-negative breast cancer:Combating a stubborn disease. Trends Pharmacol Sci 2015; 36:822-46; PMID:26538316; http://dx.doi.org/10.1016/j.tips.2015.08.009
3. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, et al. Molecular portraits of human breast tumours. Nature 2000; 406:747-52; PMID:10963602; http://dx.doi.org/10.1038/35021093
4. Chacon RD, Costanzo MV. Triple-negative breast cancer. Breast Cancer Res 2010; 12(2):S3; PMID:21050424; http://dx.doi.org/10.1186/bcr2574
5. Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA, Lickley LA, Rawlinson E, Sun P, Narod SA. Triple-negative breast cancer:clinical features and patterns of recurrence. Clin Cancer Res 2007; 13:4429-34; PMID:17671126; http://dx.doi.org/10.1158/1078-0432.CCR-06-3045
6. Stoeck A, Lejnine S, Truong A, Pan L, Wang H, Zang C, Yuan J, Ware C, MacLean J, Garrett-Engele PW, et al. Discovery of biomarkers predictive of GSI response in triple-negative breast cancer and adenoid cystic carcinoma. Cancer Discov 2014; 4:1154-67; PMID:25104330; http://dx.doi.org/10.1158/2159-8290.CD-13-0830
7. Ibrahim YH, Garcia-Garcia C, Serra V, He L, Torres-Lockhart K, Prat A, Anton P, Cozar P, Guzmán M, Grueso J, et al. PI3K inhibition impairs BRCA1/2 expression and sensitizes BRCA-proficient triple-negative breast cancer to PARP inhibition. Cancer Discov 2012; 2:1036-47; PMID:22915752; http://dx.doi.org/10.1158/2159-8290.CD-11-0348
8. Dieras V, Campone M, Yardley DA, Romieu G, Valero V, Isakoff SJ, Koeppen H, Wilson TR, Xiao Y, Shames DS, et al. Randomized, phase II, placebo-controlled trial of onartuzumab and/or bevacizumab in combination with weekly paclitaxel in patients with metastatic triple-negative breast cancer. Ann Oncol 2015; 26:1904-10; PMID:26202594; http://dx.doi.org/10.1093/annonc/mdv263
9. Curigliano G, Pivot X, Cortes J, Elias A, Cesari R, Khosravan R, Collier M, Huang X, Cataruozolo PE, Kern KA, et al. Randomized phase II study of sunitinib versus standard of care for patients with previously treated advanced triple-negative breast cancer. Breast 2013; 22:650-6; PMID:23958375; http://dx.doi.org/10.1016/j.breast.2013.07.037
10. Yardley DA, Shipley DL, Peacock NW, Shastry M, Midha R, Priego VM, Hainsworth JD. Phase I/II trial of neoadjuvant sunitinib administered with weekly paclitaxel/carboplatin in patients with locally advanced triple-negative breast cancer. Breast Cancer Res Treat 2015; 152:557-67; PMID:26155975; http://dx.doi.org/10.1007/s10549-015-3482-4
11. Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, Lilenbaum R, Johnson DH. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006; 355:2542-50; PMID:17167137; http://dx.doi.org/10.1056/NEJMoa061884
12. Rini BI, Halabi S, Rosenberg JE, Stadler WM, Vaena DA, Archer L, Atkins JN, Picus J, Czaykowski P, Dutcher J, et al. Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma:final results of CALGB 90206. J Clin Oncol 2010; 28:2137-43; PMID:20368558; http://dx.doi.org/10.1200/JCO.2009.26.5561
13. Sikov WM, Berry DA, Perou CM, Singh B, Cirrincione CT, Tolaney SM, Kuzma CS, Pluard TJ, Somlo G, Port ER, et al. Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer:CALGB 40603 (Alliance). J Clin Oncol 2015; 33:13-21; PMID:25092775; http://dx.doi.org/10.1200/JCO.2014.57.0572
14. Paez-Ribes M, Allen E, Hudock J, Takeda T, Okuyama H, Vinals F, Inoue M, Bergers G, Hanahan D, Casanovas O. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 2009; 15:220-31; PMID:19249680; http://dx.doi.org/10.1016/j.ccr.2009.01.027
15. Zhang S, Zhang D, Sun B. Vasculogenic mimicry:current status and future prospects. Cancer Lett 2007; 254:157-64; PMID:17306454; http://dx.doi.org/10.1016/j.canlet.2006.12.036
16. Hendrix MJ, Seftor EA, Meltzer PS, Gardner LM, Hess AR, Kirschmann DA, Schatteman GC, Seftor RE. Expression and functional significance of VE-cadherin in aggressive human melanoma cells:role in vasculogenic mimicry. Proc Natl Acad Sci U S A 2001; 98:8018-23; PMID:11416160; http://dx.doi.org/10.1073/pnas.131209798
17. Zhang S, Guo H, Zhang D, Zhang W, Zhao X, Ren Z, Sun B. Microcirculation patterns in different stages of melanoma growth. Oncol Rep 2006; 15:15-20; PMID:16328029; http://dx.doi.org/10.3892/or.15.1.15
18. Hess AR, Seftor EA, Gardner LM, Carles-Kinch K, Schneider GB, Seftor RE, Kinch MS, Hendrix MJ. Molecular regulation of tumor cell vasculogenic mimicry by tyrosine phosphorylation:role of epithelial cell kinase (Eck/EphA2). Cancer Res 2001; 61:3250-5; PMID:11309274; http://cancerres.aacrjournals.org/content/61/8/3250
19. Sun B, Qie S, Zhang S, Sun T, Zhao X, Gao S, Ni C, Wang X, Liu Y, Zhang L. Role and mechanism of vasculogenic mimicry in gastrointestinal stromal tumors. Hum Pathol 2008; 39:444-51; PMID:18261629; http://dx.doi.org/10.1016/j.humpath.2007.07.018
20. Shirakawa K, Kobayashi H, Sobajima J, Hashimoto D, Shimizu A, Wakasugi H. Inflammatory breast cancer:vasculogenic mimicry and its hemodynamics of an inflammatory breast cancer xenograft model. Breast Cancer Res 2003; 5:136-9; PMID:12793894; http://dx.doi.org/10.1186/bcr585
21. Sun T, Zhao N, Zhao XL, Gu Q, Zhang SW, Che N, Wang XH, Du J, Liu YX, Sun BC. Expression and functional significance of Twist1 in hepatocellular carcinoma:its role in vasculogenic mimicry. Hepatology 2010; 51:545-56; PMID:19957372; http://dx.doi.org/10.1002/hep.23311
22. Sun T, Sun BC, Zhao XL, Zhao N, Dong XY, Che N, Yao Z, Ma YM, Gu Q, Zong WK, et al. Promotion of tumor cell metastasis and vasculogenic mimicry by way of transcription coactivation by Bcl-2 and Twist1:a study of hepatocellular carcinoma. Hepatology 2011; 54:1690-706; PMID:21748764; http://dx.doi.org/10.1002/hep.24543
23. Liu X, Wang X, Du W, Chen L, Wang G, Cui Y, Liu Y, Dou Z, Wang H, Zhang P, et al. Suppressor of fused (Sufu) represses Gli1 transcription and nuclear accumulation, inhibits glioma cell proliferation, invasion and vasculogenic mimicry, improving glioma chemo-sensitivity and prognosis. Oncotarget 2014; 5:11681-94; PMID:25373737; http://dx.doi.org/10.18632/oncotarget.2585
24. Orecchia P, Conte R, Balza E, Pietra G, Mingari MC, Carnemolla B. Targeting Syndecan-1, a molecule implicated in the process of vasculogenic mimicry, enhances the therapeutic efficacy of the L19-IL2 immunocytokine in human melanoma xenografts. Oncotarget 2015; 6:37426-42; PMID:26460958; http://dx.doi.org/10.18632/oncotarget.6055
25. Zhang D, Sun B, Zhao X, Ma Y, Ji R, Gu Q, Dong X, Li J, Liu F, Jia X, et al. Twist1 expression induced by sunitinib accelerates tumor cell vasculogenic mimicry by increasing the population of CD133+ cells in triple-negative breast cancer. Mol Cancer 2014; 13:207; PMID:25200065; http://dx.doi.org/10.1186/1476-4598-13-207
26. Wang Z, Dabrosin C, Yin X, Fuster MM, Arreola A, Rathmell WK, Generali D, Nagaraju GP, El-Rayes B, Ribatti D, et al. Broad targeting of angiogenesis for cancer prevention and therapy. Semin Cancer Biol 2015; 35:S224-43; PMID:25600295; http://dx.doi.org/10.1016/j.semcancer.2015.01.001
27. Vasudev NS, Goh V, Juttla JK, Thompson VL, Larkin JM, Gore M, Nathan PD, Reynolds AR. Changes in tumour vessel density upon treatment with anti-angiogenic agents:relationship with response and resistance to therapy. Br J Cancer 2013; 109:1230-42; PMID:23922108; http://dx.doi.org/10.1038/bjc.2013.429
28. Conley SJ, Gheordunescu E, Kakarala P, Newman B, Korkaya H, Heath AN, Clouthier SG, Wicha MS. Antiangiogenic agents increase breast cancer stem cells via the generation of tumor hypoxia. Proc Natl Acad Sci U S A 2012; 109:2784-9; PMID:22308314; http://dx.doi.org/10.1073/pnas.1018866109
29. Soeda A, Park M, Lee D, Mintz A, Androutsellis-Theotokis A, McKay RD, Engh J, Iwama T, Kunisada T, Kassam AB, et al. Hypoxia promotes expansion of the CD133-positive glioma stem cells through activation of HIF-1alpha. Oncogene 2009; 28:3949-59; PMID:19718046; http://dx.doi.org/10.1038/onc.2009.252
30. McIntyre A, Harris AL. Metabolic and hypoxic adaptation to anti-angiogenic therapy:a target for induced essentiality. EMBO Mol Med 2015; 7:368-79; PMID:25700172; http://dx.doi.org/10.15252/emmm.201404271
31. Bergers G, Hanahan D. Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer 2008; 8:592-603; PMID:18650835; http://dx.doi.org/10.1038/nrc2442
32. Vasudev NS, Reynolds AR. Anti-angiogenic therapy for cancer:current progress, unresolved questions and future directions. Angiogenesis 2014; 17:471-94; PMID:24482243; http://dx.doi.org/10.1007/s10456-014-9420-y
33. Seftor RE, Hess AR, Seftor EA, Kirschmann DA, Hardy KM, Margaryan NV, Hendrix MJ. Tumor cell vasculogenic mimicry:from controversy to therapeutic promise. Am J Pathol 2012; 181:1115-25; PMID:22944600; http://dx.doi.org/10.1016/j.ajpath.2012.07.013
34. Singleton DC, Rouhi P, Zois CE, Haider S, Li JL, Kessler BM, Cao Y, Harris AL. Hypoxic regulation of RIOK3 is a major mechanism for cancer cell invasion and metastasis. Oncogene 2015; 34:4713-22; PMID:25486436; http://dx.doi.org/10.1038/onc.2014.396
35. Chaturvedi P, Gilkes DM, Takano N, Semenza GL. Hypoxia-inducible factor-dependent signaling between triple-negative breast cancer cells and mesenchymal stem cells promotes macrophage recruitment. Proc Natl Acad Sci U S A 2014; 111:E2120-9; PMID:24799675; http://dx.doi.org/10.1073/pnas.1406655111
36. Hwang-Verslues WW, Chang PH, Jeng YM, Kuo WH, Chiang PH, Chang YC, Hsieh TH, Su FY, Lin LC, Abbondante S, et al. Loss of corepressor PER2 under hypoxia up-regulates OCT1-mediated EMT gene expression and enhances tumor malignancy. Proc Natl Acad Sci U S A 2013; 110:12331-6; PMID:23836662; http://dx.doi.org/10.1073/pnas.1222684110
37. Kirschmann DA, Seftor EA, Hardy KM, Seftor RE, Hendrix MJ. Molecular pathways:vasculogenic mimicry in tumor cells:diagnostic and therapeutic implications. Clin Cancer Res 2012; 18:2726-32; PMID:22474319; http://dx.doi.org/10.1158/1078-0432.CCR-11-3237
38. Seftor RE, Seftor EA, Koshikawa N, Meltzer PS, Gardner LM, Bilban M, Stetler-Stevenson WG, Quaranta V, Hendrix MJ. Cooperative interactions of laminin 5 gamma2 chain, matrix metalloproteinase-2, and membrane type-1-matrix/metalloproteinase are required for mimicry of embryonic vasculogenesis by aggressive melanoma. Cancer Res 2001; 61:6322-7; PMID:11522618; http://cancerres.aacrjournals.org/content/61/17/6322.long
39. Wang H, Sun W, Zhang WZ, Ge CY, Zhang JT, Liu ZY, Fan YZ. Inhibition of tumor vasculogenic mimicry and prolongation of host survival in highly aggressive gallbladder cancers by norcantharidin via blocking the ephrin type a receptor 2/focal adhesion kinase/paxillin signaling pathway. PLoS One 2014; 9:e96982; PMID:24811250; http://dx.doi.org/10.1371/journal.pone.0096982
40. Sun D, Sun B, Liu T, Zhao X, Che N, Gu Q, Dong X, Yao Z, Li R, Li J, et al. Slug promoted vasculogenic mimicry in hepatocellular carcinoma. J Cell Mol Med 2013; 17:1038-47; PMID:23815612; http://dx.doi.org/10.1111/jcmm.12087
41. Du J, Sun B, Zhao X, Gu Q, Dong X, Mo J, Sun T, Wang J, Sun R, Liu Y. Hypoxia promotes vasculogenic mimicry formation by inducing epithelial-mesenchymal transition in ovarian carcinoma. Gynecol Oncol 2014; 133:575-83; PMID:24589413; http://dx.doi.org/10.1016/j.ygyno.2014.02.034
42. Qi H, Sun B, Zhao X, Du J, Gu Q, Liu Y, Cheng R, Dong X. Wnt5a promotes vasculogenic mimicry and epithelial-mesenchymal transition via protein kinase Calpha in epithelial ovarian cancer. Oncol Rep 2014; 32:771-9; PMID:24898696; http://dx.doi.org/10.3892/or.2014.3229
43. Sun B, Zhang S, Zhang D, Li Y, Zhao X, Luo Y, Guo Y. Identification of metastasis-related proteins and their clinical relevance to triple-negative human breast cancer. Clin Cancer Res 2008; 14:7050-9; PMID:18981002; http://dx.doi.org/10.1158/1078-0432.CCR-08-0520